Position in CRMD
as of Mar 31, 2026
· filed May 4, 2026
Position Value
$237,106
-$40,525 QoQ
Shares Held
34,920
+46.3% QoQ
Ownership
0.045%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in CRMD Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Sigma Planning Corp holds $11,058,625 across 16 Biotechnology names. CRMD ranks #14 (2.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
7,297 | $1,669,042 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,012 | $1,554,551 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
|
20,592 | $1,330,860 | |
| 4 | SRPT |
Sarepta Therapeutics, Inc.
|
61,060 | $1,328,665 | |
| 5 | MRNA |
Moderna, Inc.
|
25,705 | $1,305,814 | |
| 6 | LGND |
Ligand Pharmaceuticals Inc
|
4,500 | $898,425 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,062 | $474,225 | |
| 8 | RNTX |
Rein Therapeutics, Inc.
|
348,677 | $453,280 |
All Filings in CRMD
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $237,106 | 34,920 | Shares | Sole | 2026-05-04 | |
| 2025-12-31 | $277,631 | 23,872 | Shares | Sole | 2026-01-30 | |
| 2025-09-30 | $309,718 | 26,631 | Shares | Sole | 2025-11-10 | |
| 2025-06-30 | $337,173 | 27,368 | Shares | Sole | 2025-08-05 | |
| 2025-03-31 | $223,638 | 36,305 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $272,913 | 33,693 | Shares | Sole | 2025-02-03 | |
| 2024-09-30 | $322,771 | 39,947 | Shares | Sole | 2024-11-04 | |
| 2024-06-30 | $139,720 | 32,268 | Shares | Sole | 2024-08-06 | |
| 2024-03-31 | $132,813 | 31,324 | Shares | Sole | 2024-05-02 | |
| No filing history on record for this holder in this stock. | ||||||